West Pharmaceutical Stock: It Beat & RAISED on the GLP-1 Boom — Is WST a Buy Now?

West Pharmaceutical Services (WST) Q2 2026 — West Pharmaceutical Services (WST), the near-monopoly maker of the elastomer stoppers, seals and delivery devices inside injectable drugs, reported a strong Q2 2026: adjusted EPS of $2.37 beat the ~$2.08 estimate (+29% YoY) on net sales of $872.3M (+13.8% reported, +12.7% organic), as High-Value Product Components (+19%) and Delivery Devices (+30%) rode the biologics and GLP-1 boom. Management RAISED full-year guidance — adjusted EPS to $8.85–$9.05 and sales to $3.35–$3.38B. The stock spiked to a record near $385 on the print, then faded to ~$364 (+1.6%). The catch: at ~41x forward earnings and ~50x free cash flow, even our optimistic compounder DCF lands near $290 — below the price. Our call: HOLD. West Pharmaceutical Services is the quiet monopoly behind injectable medicine — the world leader in the elastomer stoppers, seals, plungers, syringes and wearable delivery devices that contain and deliver the drug inside almost every vial and pre-filled syringe on earth. It's the ultimate picks-and-shovels play on biologics and GLP-1 obesity drugs: once a component is validated into an FDA-approved injectable, it's regulated-in for a decade, so West wins no matter which drug wins. Q2 2026 was a genuinely strong quarter: adjusted EPS of $2.37 beat the ~$2.08 estimate (+29% YoY), net sales rose 13.8% to $872.3M (+12.7% organic), gross margin expanded to ~38%, and operating profit rose 16.5% to $179M. The engine was High-Value Products: HVP Components grew 19% to $424M (49% of sales) and HVP Delivery Devices jumped 30% to $131M, driven by biologics strength, EU Annex 1 upgrades, and growing GLP-1 elastomers — the destocking hangover of 2023–24 is finally over. Management RAISED full-year 2026 guidance across the board: adjusted EPS to $8.85–$9.05 (from $8.40–$8.75) and net sales to $3.35–$3.38B (~10–11% organic). The balance sheet is a fortress (net cash), and capex is rolling off from a ~$380M peak toward $250–275M, which should lift free cash flow toward $500M+. So the debate isn't quality — it's price. After a 60%+ run off the $224 low, WST trades near 41x forward earnings and ~50x free cash flow, and it faded a record-high pop on this clean beat. Even giving West full credit for the GLP-1 compounder path, our owner-earnings DCF lands fair value near $290 — roughly 20–25% below today's ~$364. A wonderful company with no margin of safety. Our call: HOLD, 3/5. We're more cautious than the Street's bullish ~$370 target (Buy, ~11 of 15 analysts) — and note West's own buyback averaged $258 a share this year, well below today's price. Own it for the quality, add on real weakness toward the high $200s, and watch the GLP-1 and biologics volumes. Not financial advice. THE CALL: HOLD (3/5, A WONDERFUL MONOPOLY, PRICED FOR PERFECTION — A BEAT-AND-RAISE WITH NO MARGIN OF SAFETY) — base-case value ~$290 vs ~$364 today. KEY METRICS: - Adjusted EPS $2.37 beat ~$2.08 (+29% YoY); GAAP diluted EPS $2.15 (+18%) - Net sales $872.3M, +13.8% reported / +12.7% organic - Proprietary Products +16.6% to $722.6M (op profit +31%); West Vantage +2% to $149.7M (profit fell) - HVP Components +19% to $424M (49% of sales); HVP Delivery Devices +30% to $131M - FY2026 guidance RAISED: adj EPS $8.85–$9.05 (from $8.40–$8.75); sales $3.35–$3.38B (~10–11% organic) - Q2 operating cash flow $214M, free cash flow $128M; net-cash balance sheet (~$233M) - H1 2026 buybacks $454M at avg $258/share — well below today's ~$364 - Valuation ~41x forward EPS, ~50x FCF; our owner-earnings DCF fair value ~$290 What to watch: hard evidence the GLP-1 and biologics volume boom is long and durable — the high-value product mix and pricing sticking, delivery-device and elastomer growth compounding, and free cash flow marching past $500M as capex rolls off — which would justify the premium multiple and prompt an upgrade; the risk to respect is a repeat of the 2023–24 destocking cycle, where customers over-order and inventories bloat, which at ~41x earnings and ~50x free cash flow could re-rate the stock hard Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.